OrganiGram Holdings Inc. (OGI)
USD 1.47
(-8.7%)
USD 1.47
(-8.7%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 35.07 Million CAD | 11.1% |
| 2022 | 31.56 Million CAD | 211.16% |
| 2021 | -28.39 Million CAD | 49.73% |
| 2020 | -56.49 Million CAD | -216.55% |
| 2019 | 48.46 Million CAD | 281.02% |
| 2018 | -26.77 Million CAD | -756.23% |
| 2017 | -3.12 Million CAD | -158.84% |
| 2016 | 5.31 Million CAD | 721.16% |
| 2015 | 647.16 Thousand CAD | 335.41% |
| 2014 | -274.9 Thousand CAD | 0.0% |
| 2013 | - CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 6.7 Million CAD | 152.57% |
| 2024 Q2 | -908 Thousand CAD | -113.55% |
| 2024 Q3 | -805 Thousand CAD | 1642.73% |
| 2023 Q3 | -4.69 Million CAD | -147.92% |
| 2023 FY | -33.8 Million CAD | -207.09% |
| 2023 Q1 | 23.88 Million CAD | 67.64% |
| 2023 Q2 | 9.8 Million CAD | -58.96% |
| 2023 Q4 | -12.74 Million CAD | -171.36% |
| 2022 Q2 | 9.06 Million CAD | 1386.72% |
| 2022 Q3 | 7.64 Million CAD | -15.73% |
| 2022 Q4 | 14.24 Million CAD | 86.44% |
| 2022 FY | 31.56 Million CAD | 211.16% |
| 2022 Q1 | 610 Thousand CAD | -81.8% |
| 2021 Q4 | 3.35 Million CAD | 58.14% |
| 2021 Q1 | -16.67 Million CAD | 42.02% |
| 2021 Q2 | -17.19 Million CAD | -3.12% |
| 2021 FY | -28.39 Million CAD | 49.73% |
| 2021 Q3 | 2.11 Million CAD | 112.32% |
| 2020 FY | -56.49 Million CAD | -216.55% |
| 2020 Q1 | 11.19 Million CAD | 201.24% |
| 2020 Q2 | 11.28 Million CAD | 0.84% |
| 2020 Q3 | -50.21 Million CAD | -544.86% |
| 2020 Q4 | -28.75 Million CAD | 42.74% |
| 2019 FY | 48.46 Million CAD | 281.02% |
| 2019 Q2 | 7.95 Million CAD | 129.62% |
| 2019 Q4 | -11.05 Million CAD | -6077.09% |
| 2019 Q3 | -179 Thousand CAD | -102.25% |
| 2019 Q1 | -26.86 Million CAD | 0.21% |
| 2018 Q3 | -4.54 Million CAD | -589.79% |
| 2018 Q4 | -26.92 Million CAD | -491.87% |
| 2018 FY | -26.77 Million CAD | -756.23% |
| 2018 Q2 | 928.77 Thousand CAD | -42.59% |
| 2018 Q1 | 1.61 Million CAD | 91.51% |
| 2017 FY | -3.12 Million CAD | -158.84% |
| 2017 Q4 | 844.78 Thousand CAD | 211.53% |
| 2017 Q1 | 762.89 Thousand CAD | -55.72% |
| 2017 Q2 | -3.97 Million CAD | -621.35% |
| 2017 Q3 | -757.41 Thousand CAD | 80.96% |
| 2016 Q4 | 1.72 Million CAD | 8.92% |
| 2016 FY | 5.31 Million CAD | 721.16% |
| 2016 Q3 | 1.58 Million CAD | 46.12% |
| 2016 Q2 | 1.08 Million CAD | 68.94% |
| 2016 Q1 | 640.83 Thousand CAD | 1.58% |
| 2015 Q2 | 10.83 Thousand CAD | 106.34% |
| 2015 Q1 | -170.91 Thousand CAD | 37.59% |
| 2015 FY | 647.16 Thousand CAD | 335.41% |
| 2015 Q4 | 630.89 Thousand CAD | 429.07% |
| 2015 Q3 | -191.72 Thousand CAD | -1869.12% |
| 2014 Q3 | -1051.00 CAD | 0.0% |
| 2014 Q2 | - CAD | 0.0% |
| 2014 Q1 | - CAD | 0.0% |
| 2014 Q4 | -273.85 Thousand CAD | -25956.52% |
| 2014 FY | -274.9 Thousand CAD | 0.0% |
| 2013 FY | - CAD | 0.0% |
| 2013 Q3 | - CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q4 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2012 Q3 | - CAD | 0.0% |
| 2012 Q4 | - CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2011 Q1 | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Theratechnologies Inc. | 62.12 Million USD | 43.548% |
| Harrow Health, Inc. | 90.55 Million USD | 61.268% |
| Dynavax Technologies Corporation | 182.11 Million USD | 80.741% |
| Biofrontera Inc. | 16.62 Million USD | -110.941% |
| Cronos Group Inc. | 6.99 Million USD | -401.699% |
| Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -639.162% |
| Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 92.05% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 11675.324% |
| RedHill Biopharma Ltd. | 3.05 Million USD | -1048.371% |
| Cumberland Pharmaceuticals Inc. | 33.48 Million USD | -4.74% |
| Radius Health, Inc. | 307.71 Million USD | 88.602% |
| Universe Pharmaceuticals INC | 10.07 Million USD | -248.022% |
| DURECT Corporation | 6.83 Million USD | -413.442% |
| ProPhase Labs, Inc. | 16.23 Million USD | -115.981% |
| Safety Shot Inc | -74.45 Thousand USD | 47205.353% |
| Phibro Animal Health Corporation | 312.48 Million USD | 88.776% |
| China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -6231.24% |
| Alvotech | -69.42 Million USD | 150.522% |
| Assertio Holdings, Inc. | 125.04 Million USD | 71.952% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 93.303% |
| Rockwell Medical, Inc. | 8.7 Million USD | -302.955% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -320.584% |
| Procaps Group S.A. | 239.56 Million USD | 85.36% |
| Intra-Cellular Therapies, Inc. | 430.62 Million USD | 91.855% |
| SCYNEXIS, Inc. | 124.51 Million USD | 71.833% |
| Aytu BioPharma, Inc. | 54.58 Million USD | 35.747% |
| Viatris Inc. | 6.43 Billion USD | 99.455% |
| OptiNose, Inc. | 62.35 Million USD | 43.751% |
| SIGA Technologies, Inc. | 122.09 Million USD | 71.273% |
| Tilray Brands, Inc. | 223.35 Million USD | 84.297% |
| PetIQ, Inc. | 252.74 Million USD | 86.123% |
| Sunshine Biopharma, Inc. | 8.33 Million USD | -320.584% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 98.101% |
| Guardion Health Sciences, Inc. | 5.39 Million USD | -550.164% |
| Alimera Sciences, Inc. | 61.17 Million USD | 42.663% |
| Collegium Pharmaceutical, Inc. | 326.16 Million USD | 89.247% |
| Silver Spike Investment Corp. | 8.1 Million USD | -332.864% |
| Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 515049.831% |
| Organogenesis Holdings Inc. | 309.79 Million USD | 88.678% |
| Journey Medical Corporation | 52.52 Million USD | 33.221% |
| Petros Pharmaceuticals, Inc. | 4.19 Million USD | -736.837% |
| Alpha Teknova, Inc. | 10.29 Million USD | -240.649% |
| Clever Leaves Holdings Inc. | 6.55 Million USD | -434.979% |
| Lifecore Biomedical, Inc. | 41.85 Million USD | 16.193% |
| PainReform Ltd. | -15 Thousand USD | 233921.553% |
| Cosmos Health Inc. | 4.34 Million USD | -706.361% |
| Avadel Pharmaceuticals plc | 27.11 Million USD | -29.34% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -2593.797% |
| Embecta Corp. | 749.9 Million USD | 95.323% |
| Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 4804.104% |
| Talphera, Inc. | -4.89 Million USD | 816.511% |
| Pacira BioSciences, Inc. | 490.3 Million USD | 92.847% |
| Incannex Healthcare Limited | 12 Thousand USD | -292176.942% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 1555.215% |
| Shineco, Inc. | 882.16 Thousand USD | -3875.8% |
| Procaps Group, S.A. | 239.56 Million USD | 85.36% |
| ANI Pharmaceuticals, Inc. | 305.3 Million USD | 88.512% |
| Aquestive Therapeutics, Inc. | 29.75 Million USD | -17.885% |
| Lantheus Holdings, Inc. | 709.54 Million USD | 95.057% |
| Alvotech | -69.42 Million USD | 150.522% |
| Hempacco Co., Inc. | -1.21 Million USD | 2984.708% |
| Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 84.178% |
| Bright Green Corporation | -237.01 Thousand USD | 14897.833% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 51.999% |
| Kamada Ltd. | 52.59 Million USD | 33.312% |
| Indivior PLC | 907 Million USD | 96.133% |
| Evoke Pharma, Inc. | 4.97 Million USD | -604.458% |
| Flora Growth Corp. | 17.73 Million USD | -97.729% |
| Cyclo Therapeutics, Inc. | -2.41 Million USD | 1555.215% |
| Evolus, Inc. | 140.52 Million USD | 75.041% |
| HUTCHMED (China) Limited | 453.55 Million USD | 92.267% |
| Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 89.803% |
| Akanda Corp. | 111.44 Thousand USD | -31370.209% |